All the Active Ingredient Drugs
Human Monoclonal Antibody. Evolocumab 140 mg/ml. PRE-FILL.SYR.or PEN:1, 2, 3, 6 X 1ml.
Prim. hypercholesterolem. & mixed dyslipidem. in adlts. and ped. pts. aged 10 and over: either 140 mg every two wks. or 420 mg once month. ; both doses
are clinic. equiv.
Homozyg. famil. hypercholesterolem. in adult. and ped. pts. ≥ 10 yrs.:
init. recomm. dose is 420 mg once month. After 12 wks. of tmt., dose freq. can be up-titrat. to 420 mg once every 2 wks. if clinic. meaningful resp. is not achieved. Pts. on apheresis may init. tmt. with 420 mg every two wks. to corresp. with their apheresis sched.
Establish. atheroscler. cardiovasc. dis. in adult.: 140 mg every two wks. or 420 mg once month.; both doses are clinic. equiv. See lit.
Hypercholesterolem. & and mixed dyslipidem. in adults with prim. hypercholesterolem. (heterozyg. famil. and non-famil.) or mixed dyslipidem. and in ped. pts. aged 10 and over with heterozyg. fam. hyperchol. as an adj. to diet:
in comb. with a statin or statin with other lipid-low. therap. in pts. unable to reach LDL-C goals with the max. toler. dose of a statin or,
alone or in comb. with other lipid-lower. therap. in pts. who are statin-intoler., or for whom a statin is contraindic.
Homozyg. famil. hypercholesterolem. –adult. & ped. pts. aged 10 and over- in comb. with other lipid-lower. therap.
Establish. atheroscl. cardiovasc. dis.-adults with MI, stroke or peripher. arterial dis.- to red. cardiovasc. risk by lower. LDL-C levels, as an adj. to correct. of other risk factors:
in comb.with the maxim. toler. dose of a statin with / w/o other lipid-lower.
therap.
alone or in comb. with other lipid-lower. therap. in pts. who are statin-intoler., or for whom a statin is contraindic.
C/I: Hypersens.
